Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL7926726 | 0.93 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL4847926 | 0.84 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL2969896 | 0.84 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL13074753 | 0.84 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL23014488 | 0.83 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL11319921 | 0.82 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL8372267 | 0.82 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL25885547 | 0.82 | SMN1; SMN2 (0.70) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| SCHEMBL5123738 | 0.81 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| Hippuric Acid SCHEMBL28149861 | 0.81 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | claimed |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-02-03 | — | — | US | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250341515-A1 | METABOLOMIC BIOMARKERS FOR ACUTE KIDNEY INJURY, ASSAYS, COMPOSITIONS AND METHODS OF USE THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-06 | — | — | US | claimed |
| US-20250336540-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | claimed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | claimed |
| WO-2025068213-A1 | USE OF A MARKER SET FOR DETERMINING THE RISK OF HAVING OR DEVELOPING BLADDER CANCER | NUMARES AG (DE) | 2025-04-03 | — | — | WO | claimed |
| EP-4515242-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN Pharmaceutica NV (BE) | 2025-03-05 | — | — | EP | claimed |
| CN-119165074-A | NSCLC patient typing and third generation EGFR-TKI efficacy prediction model based on T790M mutation of plasma metabolite | 中国医学科学院北京协和医院 | 2024-12-20 | — | — | CN | claimed |
| EP-4440563-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-10-09 | — | — | EP | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| CN-1212019-A | Methods and compositions for detecting ligand pair binding using non-fluorescent labels | RAPIGENE INC (US) | 1999-03-24 | — | — | CN | claimed |
| CN-1212021-A | Method and compositions for determining sequence of nucleic acid molecules | RAPIGENE INC (US) | 1999-03-24 | — | — | CN | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| US-5686311-A | ANALYZING FLUID SAMPLE | THE CHILDREN'S MERCY HOSPITAL (US) | 1997-11-11 | — | — | US | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | LIPC, GGT1, TGM2 | ALDH1A1 422/4885SMN1; SMN2 2843/4885RAB9A 3593/4885 |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | LIPC, GGT1, TGM2 | ALDH1A1 502/4885SMN1; SMN2 3433/4885RAB9A 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.